# Effect of Dronedarone on Atrial Fibrosis Progression and Atrial Fibrillation Recurrence

> **NCT04704050** · PHASE4 · TERMINATED · sponsor: **Tulane University School of Medicine** · enrollment: 22 (actual)

## Conditions studied

- Atrial Fibrillation
- Atrial Fibrillation Recurrent

## Interventions

- **DRUG:** dronedarone 400 mg Oral Tablet
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04704050
- **Lead sponsor:** Tulane University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-05-15
- **Primary completion:** 2022-12-20
- **Final completion:** 2022-12-20
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Sponsor withdrew funding
- **Last updated:** 2025-10-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04704050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04704050, "Effect of Dronedarone on Atrial Fibrosis Progression and Atrial Fibrillation Recurrence". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT04704050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*